Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later (original) (raw)

Abstract

In March 2005, the Remission in Schizophrenia Working Group (RSWG) proposed a consensus definition of symptomatic remission in schizophrenia and developed specific operational criteria for its assessment. They pointed out, however, that the validity and the ...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (71)

  1. Remission in schizophrenia -Lambert et al Dialogues in Clinical Neuroscience -Vol 12 . No. 3 . 2010 REFERENCES
  2. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizo- phrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.
  3. Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remis-sion. J Psychopharmacol. 2006;20(6 suppl):57-61.
  4. Lasser RA, Nasrallah H, Helldin L, et al. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res. 2007;96:223-231.
  5. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remis- sion in schizo-phrenia: recommendations for their use and their presenta- tion.
  6. Acta Psychiatr Scand (suppl). 2009;438:7-14.
  7. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 2006;113:91-95.
  8. Sethuraman G, Taylor CC, Enerson M, et al. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperi- done among patients with schizophrenia. Schizophr Res. 2005;79:337-340.
  9. Dunayevich E, Sethuraman G, Enerson M, et al. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res. 2006;86:300-308.
  10. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsy- chotic drugs in treatment-naive first-episode schizophrenia: a 52-week ran- domized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
  11. van Os J, Drukker M, à Campo J, et al. Validation of remission criteria for schizophrenia. Am J Psychiatry. 2006;163:2000-2002.
  12. Leucht S, Beitinger R, Kissling W. On the concept of remission in schiz- ophrenia. Psychopharmacology (Berl). 2007;194:453-461.
  13. Liberman R, Kopelowicz A, Ventura J, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14:256-272.
  14. Beitinger R, Lin J, Kissling W, Leucht S. Comparative remission fre- quencies of schizo-phrenic patients using various remission criteria. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1643-1651.
  15. Cassidy CM, Norman R, Manchanda R, et al. Testing definitions of symp- tom remission in first-episode psychosis for prediction of functional out- come at 2 years. Schizophr Bull. 2010;36:1001-1008.
  16. Helldin L, Kane JM, Karilampi U, et al. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res. 2006;40:738-745.
  17. Helldin L, Kane JM, Karilampi U, et al. Remission in prognosis of func- tional outcome: a new dimension in the treatment of patients with psy- chotic disorders. Schizophr Res. 2007;93:160-168.
  18. Ciudad A, Alvarez E, Bobes J, et al. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res. 2009;108:214- 222.
  19. Buckley PF, Harvey PD, Bowie CR, et al. The relationship between symp- tomatic remission and neuropsychological improvement in schizophrenia patients switched to treat-ment with ziprasidone. Schizophr Res. 2007;94:99- 106.
  20. Emsley R, Rabinowitz J, Medori R et al. Remission in early psychosis: fre- quencies, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89:129-139.
  21. Kelly DL, Weiner E, Ball MP, et al. Remission in schizophrenia: the rela- tionship to base-line symptoms and changes in symptom domains during a one-year study. J Psychopharmacol. 2009;23:436-441.
  22. Opler MGA,Yang LH, Caleo S et al. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry. 2007;7:35.
  23. Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005;77:215-227.
  24. Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schiz- ophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res. 2007;95:143-150.
  25. De Hert M, van Winkel R, Wampers M, et al. Remission criteria for schiz- ophrenia: evaluation in a large naturalistic cohort. Schizophr Res. 2007;92:68-73.
  26. Wunderink L, Nienhuis FJ, Sytema S, et al. Predictive validity of pro- posed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull. 2007;33:792-796.
  27. Emsley R, Oosthuizen PP, Kidd M, et al. Remission in first-episode psy- chosis: predictor variables and symptom improvement patterns. J Clin Psychiatry. 2006;67:1707-1712.
  28. Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res. 2008;106:281-285.
  29. Helldin L, Kane JM, Hjärthag F, et al. The importance of cross-sectional remission in schizophrenia for long-term outcome: a clinical prospective study. Schizophr Res. 2009;115:67-73.
  30. Eberhard J, Levander S, Lindström E. Remission in schizophrenia: analy- sis in a naturalistic setting. Compr Psychiatry. 2009;50:200-208.
  31. Bodén R, Sundström J, Lindström E, et al. Association between symp- tomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107:232-237.
  32. Bobes J, Ciudad A, Alvarez E, et al. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophr Res. 2009;115:58-66.
  33. San L, Ciudad A, Alvarez E, et al. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry. 2007;22:490-498.
  34. Wunderink L, Sytema S, Nienhuis FJ, et al. Clinical recovery in first- episode psychosis. Schizophr Bull. 2009;35:362-369.
  35. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690-1697.
  36. Catty J, Lissouba P, White S, et al. Predictors of employment for people with severe mental illness: results of an international six-centre randomised controlled trial. Br J Psychiatry. 2008;192:224-231.
  37. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone--analysis of long-term efficacy. J Psychopharmacol. 2005;19(5 Suppl):15-21.
  38. Rossi A, Bagalà A, Del Curatolo V, et al. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009;24:574-583.
  39. Caton CL, Hasin DS, Shrout PE, et al. Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophr Bull. 2006;32:618-625.
  40. Cohen CI, Pathak R, Ramirez PM, et al. Outcome among community dwelling older adults with schizophrenia: results using five conceptual mod- els. Community Ment Health J. 2009;45:151-156.
  41. Lambert M, De Marinis T, Pfeil J, et al. Establishing remission and good clinical func-tioning in schizophrenia: predictors of best outcome with long- term risperidone long-acting injectable treatment. Eur Psychiatry. 2010;25:220-229.
  42. Gasquet I, Haro JM, Tcherny-Lessenot S, et al. Remission in the outpa- tient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur Psychiatry. 2008;23:491-496.
  43. Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115:97-103.
  44. Menezes NM, Malla AM, Norman RM, et al. A multi-site Canadian per- spective: examin-ing the functional outcome from first-episode psychosis. Acta Psychiatr Scand. 2009;120:138-146.
  45. Bachmann S, Bottmer C, Schroder J. One-year outcome and its predic- tion in first-episode schizophrenia--a naturalistic study. Psychopathology. 2008;41:115-123.
  46. Petersen L, Thorup A, Øqhlenschlaeger J, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2- year follow-up of the OPUS trial. Can J Psychiatry. 2008;53:660-670.
  47. Malla A, Norman R, Schmitz N, et al. Predictors of frequency and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006;36:649-658.
  48. Novick D, Haro JM, Suarez D, et al. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl). 2007;191:1015-1022.
  49. Lambert M, Naber D, Schacht A, et al. Frequencys and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118:220-229.
  50. de Haan L, Nimwegen L, Amelsvoort T, et al. Improvement of subjec- tive well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41:125-128.
  51. Crumlish N, Whitty P, Clarke M, et al. Beyond the critical period: longi- tudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry. 2009;194:18-24.
  52. Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108:223-230.
  53. Emsley R, Chiliza B, Schoeman R. Predictors of long-term outcome in schizophrenia. Curr Op Psychiatry. 2008; 21:173-177.
  54. Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor in-sight in patients with schizophrenia. A systematic review. Schizophr Bull. 2007;33:1324-1342.
  55. Holthausen EA, Wiersma D, Cahn W, et al. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007;149:71-80 .
  56. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635-645.
  57. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:473-479.
  58. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longi- tudinal outcome studies of first-episode psychosis. Psychol Med. 2006; 36:1349-1362.
  59. Whitty P, Clarke M, McTigue O, et al. Predictors of outcome in first- episode schizophrenia over the first 4 years of illness. Psychol Med. 2008;38:1141-1146.
  60. Rosen K, Garety P. Predicting recovery from schizophrenia: a retro- spective comparison of characteristics at onset of people with single and multiple episodes. Schizophr Bull. 2005;31:735-750.
  61. White C, Stirling J, Hopkins R, et al. Predictors of 10-year outcome of first-episode psychosis. Psychol Med. 2009;39:1447-1456.
  62. Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108:223-230.
  63. Karow A, Naber D, Lambert M, Moritz S. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry. In press.
  64. Lambert M, Eich FX, Schacht M, et al. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand. 2007;115:106-113.
  65. Lambert M, Schimmelmann B, Eich FX, et al. Early-and delayed antipsy- chotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009;42:277-283.
  66. Lambert M, Naber D, eds. Current Schizophrenia -2nd edition. London, UK: Current Medicine Group; 2009:1-156.
  67. Schimmelmann B, Conus P, Schacht M, et al. Predictors of service dis- engagement with treatment in first-admitted adolescents with psychosis. J Am Acad Child Adolesc Psychiatry. 2006;45:990-999.
  68. Conus P, Lambert M, Cotton S, et al. Rate and predictors of service dis- engagement in an epidemiological first-episode psychosis cohort. Schizophr Res. In press.
  69. Schimmelmann B, Conus P, Edwards J, et al. Diagnostic stability 18- month after a first diagnosis of psychosis. J Clin Psychiatry. 2005;66:1239-1246.
  70. Lambert M, Schimmelmann BG, Schacht A, et al. Long-term cluster of subjective well-being in schizophrenia: prediction of cluster affiliation and their predictive value for recovery in 2842 patients followed over 3 years. Schizophr Res. 2009;107:165-172.
  71. Remission in schizophrenia -Lambert et al Dialogues in Clinical Neuroscience -Vol 12 . No. 3 . 2010